ロード中...
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU a...
保存先:
| 出版年: | Allergy Asthma Clin Immunol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6724286/ https://ncbi.nlm.nih.gov/pubmed/31507641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-019-0366-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|